Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P020045/S113

Freezor 207Fl,207F3,207F5, Freezor Xtra 217Fl,217F3,217F5

Medtronic Cryocath, LP · Decision date Apr 23, 2026

FDA DECISIONP020045/S113

What did the FDA approve?

FDA records P020045/S113 as a supplement to PMA P020045, with the supplement type “Real-Time Process”. The recorded decision is approval, dated Apr 23, 2026.

FDA approval order statement

approval for Freezor Coaxial Connector Adhesive Modifications
Regulatory pathway
PMA supplement
Supplement type
Real-Time Process
Clinical specialty
Cardiovascular
Decision date
Apr 23, 2026
FDA change category
Change Design/Components/Specifications/Material

FDA source record

Regulatory record facts

Identifier
P020045/S113
Regulatory pathway
PMA supplement
Product code
LPB
Decision code
APPR
Decision date
Apr 23, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Cardiac ablation percutaneous catheter.

Product code
LPB
FDA device class
3

Review the original FDA PMA listing for the original approval scope and linked supplements.

FDA decision timeline

  1. P020045/S113 received

    Application receipt date recorded by FDA.

  2. P020045/S113 · FDA decision

    Real-Time Process

Timeline entries are records held by MedtechLedger for P020045. View FDA’s full supplement list.

Related devices and submissions

Explore the linked device profile

Other records with product code LPB

Product / regulatory recordCompanyPathwayDecision dateSource
Biosense Webster, Inc.PMA supplementSep 15, 2026FDA
Irvine Biomedical, Inc.PMA supplementSep 3, 2026FDA
Ampere GeneratorP040014/S051
Irvine Biomedical, Inc.PMA supplementAug 7, 2026FDA
Ampere GeneratorP960016/S094
St Jude MedicalPMA supplementAug 7, 2026FDA
Stereotaxis, Inc.PMA supplementJul 31, 2026FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

FDA describes the real-time supplement process as a review route for minor changes to a device, including certain design, software, sterilization or labeling changes.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Medtronic Cryocath, LP

Headquarters
Not reported
Brand website
medtronic.com
FDA applicant address
8200 Coral Sea St., Mounds View, MN, 55112

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records